Velda J González-Mercado1,2, Wendy A Henderson3, Anujit Sarkar4, Jean Lim5, Leorey N Saligan6, Lawrence Berk7, Larry Dishaw8, Susan McMillan2, Maureen Groer2, Farrah Sepehri2, Gail D'Eramo Melkus1. 1. NYU Rory Meyers College of Nursing, New York, NY, USA. 2. College of Nursing, 7831University of South Florida, Tampa, FL, USA. 3. College of Nursing, 7712University of Connecticut, Storrs, CT, USA. 4. College of Nursing and College of Public Health, 7831University of South Florida, Tampa, FL, USA. 5. 96722Rosenstiel School of Marine and Atmosphereic Science, University of Miami, FL, USA. 6. Symptom Science Center, Symptom Biology Unit, Division of Intramural Research, NINR, NIH, DHHS, Bethesda, MD, USA. 7. College of Medicine Radiology, 7831University of South Florida, Tampa, FL, USA. 8. Department of Pediatrics, Molecular Genetics Children's Research Institute, 7831University of South Florida, St. Petersburg, FL, USA.
Abstract
PURPOSE: To examine a) whether there are significant differences in the severity of symptoms of fatigue, sleep disturbance, or depression between patients with rectal cancer who develop co-occurring symptoms and those with no symptoms before and at the end of chemotherapy and radiation therapy (CRT); b) differences in gut microbial diversity between those with co-occurring symptoms and those with no symptoms; and c) whether before-treatment diversity measurements and taxa abundances can predict co-occurrence of symptoms. METHODS: Stool samples and symptom ratings were collected from 31 patients with rectal cancer prior to and at the end of (24-28 treatments) CRT. Descriptive statistics were computed and the Mann-Whitney U test was performed for symptoms. Gut microbiome data were analyzed using R's vegan package software. RESULTS: Participants with co-occurring symptoms reported greater severity of fatigue at the end of CRT than those with no symptoms. Bacteroides and Blautia2 abundances differed between participants with co-occurring symptoms and those with no symptoms. Our random forest classification (unsupervised learning algorithm) predicted participants who developed co-occurring symptoms with 74% accuracy, using specific phylum, family, and genera abundances as predictors. CONCLUSION: Our preliminary results point to an association between the gut microbiota and co-occurring symptoms in rectal cancer patients and serves as a first step in potential identification of a microbiota-based classifier.
PURPOSE: To examine a) whether there are significant differences in the severity of symptoms of fatigue, sleep disturbance, or depression between patients with rectal cancer who develop co-occurring symptoms and those with no symptoms before and at the end of chemotherapy and radiation therapy (CRT); b) differences in gut microbial diversity between those with co-occurring symptoms and those with no symptoms; and c) whether before-treatment diversity measurements and taxa abundances can predict co-occurrence of symptoms. METHODS: Stool samples and symptom ratings were collected from 31 patients with rectal cancer prior to and at the end of (24-28 treatments) CRT. Descriptive statistics were computed and the Mann-Whitney U test was performed for symptoms. Gut microbiome data were analyzed using R's vegan package software. RESULTS: Participants with co-occurring symptoms reported greater severity of fatigue at the end of CRT than those with no symptoms. Bacteroides and Blautia2 abundances differed between participants with co-occurring symptoms and those with no symptoms. Our random forest classification (unsupervised learning algorithm) predicted participants who developed co-occurring symptoms with 74% accuracy, using specific phylum, family, and genera abundances as predictors. CONCLUSION: Our preliminary results point to an association between the gut microbiota and co-occurring symptoms in rectal cancer patients and serves as a first step in potential identification of a microbiota-based classifier.
Entities:
Keywords:
chemotherapy and radiation therapy; co-occurrence of symptoms; gut microbiome; rectal cancer
Authors: Velda J González-Mercado; Anujit Sarkar; Frank J Penedo; Josué Pérez-Santiago; Susan McMillan; Sara Janet Marrero; Miguel A Marrero-Falcón; Cindy L Munro Journal: J Sleep Res Date: 2019-10-10 Impact factor: 3.981
Authors: Tracy K Gosselin; Susan Beck; David H Abbott; Steven C Grambow; Dawn Provenzale; Patricia Berry; Katherine L Kahn; Jennifer L Malin Journal: J Pain Symptom Manage Date: 2016-09-30 Impact factor: 3.612
Authors: Clement K Gwede; Brent J Small; Pamela N Munster; Michael A Andrykowski; Paul B Jacobsen Journal: Support Care Cancer Date: 2007-11-28 Impact factor: 3.603
Authors: Bradley C Johnston; Donald L Patrick; Kristian Thorlund; Jason W Busse; Bruno R da Costa; Holger J Schünemann; Gordon H Guyatt Journal: Health Qual Life Outcomes Date: 2013-12-21 Impact factor: 3.186
Authors: Clarissa Schwab; David Berry; Isabella Rauch; Ina Rennisch; Julia Ramesmayer; Eva Hainzl; Susanne Heider; Thomas Decker; Lukas Kenner; Mathias Müller; Birgit Strobl; Michael Wagner; Christa Schleper; Alexander Loy; Tim Urich Journal: ISME J Date: 2014-01-09 Impact factor: 10.302
Authors: Kelly A Shaw; Madeline Bertha; Tatyana Hofmekler; Pankaj Chopra; Tommi Vatanen; Abhiram Srivatsa; Jarod Prince; Archana Kumar; Cary Sauer; Michael E Zwick; Glen A Satten; Aleksandar D Kostic; Jennifer G Mulle; Ramnik J Xavier; Subra Kugathasan Journal: Genome Med Date: 2016-07-13 Impact factor: 11.117
Authors: Velda J Gonzalez-Mercado; Sara Marrero; Josué Pérez-Santiago; Maribel Tirado-Gómez; Miguel A Marrero-Falcón; Elsa Pedro; Leorey N Saligan Journal: P R Health Sci J Date: 2021-03 Impact factor: 0.600